Skip to content

Screening of lung cancer tumor markers based on metabolomics: a diagnostic test.

Screening of lung cancer tumor markers based on metabolomics: a diagnostic test.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900021066
Enrollment
Unknown
Registered
2019-01-27
Start date
2019-02-01
Completion date
Unknown
Last updated
2019-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

Gold Standard:Pathological examination
tumor&#32
(blood&#32
and&#32
samples).

Sponsors

The First Affiliated hospital of NanChang University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Male or female, aged 18 years; 2. The subject reads and fully understands the instructions of the patient, and signs the informed consent; 3. In the normal control group, postoperative pathological diagnosis was made for patients with pulmonary bullae and benign pulmonary lesions (non-tumor); 4. Patients in the lung cancer group were initially diagnosed with pulmonary nodules and diagnosed with lung cancer after nodulectomy; 5. Without any anti-tumor treatment.

Exclusion criteria

Exclusion criteria: 1. Patients with other malignant tumors; 2. Patients with severe metabolic diseases; 3. Emergency treatment or patient rescue; 4. Pregnancy.

Design outcomes

Primary

MeasureTime frame
Tumor biomakers;SEN,SPE?ACC?AUC of ROC;

Countries

China

Contacts

Public ContactZhang Wei

The First Affiliated Hospital of NanChang University

zhangweiliuxin@163.com+86 13707089183

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026